Revenue
No reported data
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Research & development | £12.7M | £18.0M | £25.1M | £36.4M | £36.8M | £25.9M | £19.7M | £16.8M | £17.7M | £7.9M | £5.7M |
| Operating income | −£20.1M | −£22.8M | −£32.8M | −£39.1M | −£47.9M | −£36.4M | −£26.7M | −£19.1M | −£25.7M | −£8.4M | −£6.9M |
| EBITDAderived | −£19.8M | −£22.3M | −£32.2M | −£38.4M | −£47.0M | −£35.5M | −£26.0M | −£18.8M | −£25.5M | −£8.3M | −£6.9M |
| Net income | −£29.4M | −£19.0M | −£27.6M | −£32.0M | −£40.5M | −£30.7M | −£21.4M | −£13.8M | −£23.1M | −£6.0M | −£5.3M |
| Basic EPSper diluted share | £0.00 | -£0.26 | -£0.53 | -£0.61 | -£0.78 | -£0.81 | -£0.66 | -£0.43 | -£0.89 | -£0.25 | -£0.22 |
| Diluted EPSper diluted share | £0.00 | -£0.26 | -£0.53 | -£0.61 | -£0.78 | -£0.81 | -£0.66 | -£0.43 | -£0.89 | -£0.25 | -£0.22 |